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Aim: To evaluate the efficacy and safety of mealtime or post-meal fast-acting insulin aspart (fas-
ter aspart) vs mealtime insulin aspart (IAsp), both in combination with insulin degludec, in partici-
pants with type 1 diabetes (T1D).
Methods: This multicentre, treat-to-target trial (Clinical trial registry: NCT02500706,
ClinicalTrials.gov) randomized participants to double-blind mealtime faster aspart (n = 342) or
IAsp (n = 342) or open-label post-meal faster aspart (n = 341). The primary endpoint was
change from baseline in HbA1c 26 weeks post randomization. All available information, regard-
less of treatment discontinuation, was used for evaluation of the effect.
Results: Non-inferiority for the change from baseline in HbA1c was confirmed for mealtime and
post-meal faster aspart vs IAsp (estimated treatment difference [ETD]: 95%CI, −0.02% [−0.11;
0.07] and 0.10% [0.004; 0.19], respectively). Mealtime faster aspart was superior to IAsp for
1-hour PPG increment using a meal test (ETD, −0.90 mmol/L [−1.36; –0.45]; P < 0.001). Self-
monitored 1-hour PPG increment favoured faster aspart at breakfast (ETD, −0.58 mmol/L
[−0.99; −0.17]; P = 0.006) and across all meals (−0.48 mmol/L [−0.74; −0.21]; P < 0.001).
Safety profiles and overall rate of severe or blood glucose-confirmed hypoglycaemia were simi-
lar between treatments, but significantly less hypoglycaemia was seen 3 to 4 hours after meals
with mealtime faster aspart.
Conclusion: Mealtime and post-meal faster aspart in conjunction with insulin degludec provided
effective glycaemic control compared with IAsp, with no increased safety risk. Mealtime faster
aspart provided PPG control superior to that of IAsp.
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1 | INTRODUCTION
To reduce the incidence and slow the progression of diabetes-related
complications, guidelines recommend HbA1c target levels.1–6
Achievement of the conventionally accepted HbA1c target <7.0%
(53 mmol/mol) in individuals with type 1 diabetes (T1D) usually
requires postprandial glycaemic control.4–6
Exogenous mealtime insulin administration aims to mimic the
physiological secretion pattern of insulin to control postprandial glu-
cose (PPG) excursions. There is an unmet need for mealtime insulin
that better mimics physiological control, while enhancing flexibility
and treatment convenience for patients. The development in basal
insulin analogues, including ultra-long-acting and high-concentration
insulins, such as insulin degludec (degludec) and glargine U300,7 is
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now being complemented by emergence of ultra-fast-acting mealtime
insulins. These agents incorporate modifications to insulin formula-
tions to accelerate absorption and thereby improve insulin time–
action and PPG-lowering profiles.8–12
Fast-acting insulin aspart (faster aspart) is a faster-acting mealtime
insulin with a more rapid rate of absorption into the bloodstream and
greater early-glucose-lowering effect than conventional insulin aspart
(IAsp).13 Faster aspart has been approved for use by the US Food and
Drug Administration (FDA) and the European Medicines Agency
(EMA) as treatment for diabetes in adults.
In the onset 1 trial, the efficacy and safety of faster aspart were
evaluated as part of a basal–bolus regimen with insulin detemir (dete-
mir) in participants with T1D.14 A statistically significant, yet modest,
improvement in HbA1c was observed with mealtime faster aspart
compared with IAsp after 26 weeks of treatment (estimated treat-
ment difference [ETD], −0.15% [95%CI, −0.23; −0.07]; −1.62 mmol/
mol [−2.50; −0.73]), with a superior reduction in 2-hour PPG incre-
ment during a standardized meal test.14 This improvement in glycae-
mic control was maintained after 52 weeks of treatment.15 Faster
aspart administered 20 minutes after the start of the meal was non-
inferior (0.4% margin) to mealtime IAsp regarding change in HbA1c
after 26 weeks of treatment.14
To date, no studies comparing faster aspart with IAsp in a basal–
bolus regimen with ultra-long-acting basal insulins are available. The
onset 8 study is similar in design to the onset 1 study, and aims to
evaluate the efficacy and safety of faster aspart in conjunction with
degludec in participants with T1D. The onset 8 study was designed to
quantify a population average effect, irrespective of adherence to ran-
domized treatment and ancillary therapy use. The primary objective
was to estimate the effect based on difference in HbA1c from base-
line to 26 weeks under these circumstances. As it can sometimes be
challenging to administer bolus insulin before a meal, a post-meal fas-
ter aspart arm (administration within 20 minutes after start of the
meal) was also included to further evaluate the option of administer-
ing faster aspart after a meal when needed.
2 | RESEARCH DESIGN AND METHODS
2.1 | Trial design
In this Phase 3b, multicentre, active-controlled, randomized, parallel-
group study (ClinicalTrials.gov: NCT02500706), mealtime faster aspart
was compared with mealtime IAsp, both double-blind, in adults with
T1D over 26 weeks (Figure S1 in File S1). In a third, open-label treat-
ment arm, participants received post-meal faster aspart (Figure S1 in
File S1). Faster aspart and IAsp were delivered in a basal–bolus regi-
men in conjunction with once-daily degludec. The trial was conducted
in accordance with the Declaration of Helsinki and International Con-
ference on Harmonization of Good Clinical Practice. The study was
conducted at 146 centres in 12 countries/regions (Appendix S1 in File
S1). Follow-up assessment took place 7 and 30 days after end of
treatment.
2.2 | Study population
Adults (≥18 years of age; ≥20 years in Japan and Taiwan) with T1D
were eligible for inclusion if they had received a basal–bolus insulin
regimen for at least 12 months before screening, including a basal
insulin analogue for at least 4 months before screening. Eligibility also
required HbA1c to be 7.0% to 9.5% (53–80 mmol/mol) and BMI to be
35.0 kg/m2 or less.
Key exclusion criteria included: treatment with any antidiabetic or
obesity medication, other than listed inclusion criteria, within
3 months before screening; any anticipated change in concomitant
medications known to affect glucose metabolism persisting beyond
2 weeks of study inclusion; myocardial infarction, stroke or hospitali-
zation for unstable angina and/or transient ischaemic attack within
180 days before screening; use of continuous glucose monitoring;
inadequately-treated hypertension (≥Class 2) or clinically significant
hepatic or renal insufficiency (full criteria in Appendix S1, File S1).
2.3 | Interventions
2.3.1 | Basal titration during the trial
After a two-week screening period, an eight-week run-in period
allowed for basal insulin titration, and participants switched from their
existing basal insulin analogue to degludec (100 U/mL, 3-mL pen
injector) at the start, based on protocol-specified guidelines (Table S1
in File S1). During the run-in period, the investigator titrated degludec
on a weekly basis to the pre-breakfast glycaemic target of 4.0 to
5.0 mmol/L in accordance with titration guidelines (Table S2 in File
S1). Further adjustment of degludec during the treatment period was
performed at the investigator's discretion.
2.3.2 | Bolus dosing during the trial
At the start of the run-in period, participants switched from their pre-
vious bolus insulin to IAsp (all bolus insulins supplied as 100 U/mL,
3-mL pen injector) on a unit-for-unit basis. IAsp dose was not adjusted
during the run-in period unless considered necessary by the investiga-
tor. At the end of the run-in period, participants with HbA1c at 9.5%
(80 mmol/mol) or less were randomized 1:1:1 to receive double-blind
mealtime IAsp, double-blind mealtime faster aspart or open-label
post-meal faster aspart. Mealtime insulins were injected 0 to 2 minutes
before a meal, while post-meal faster aspart was injected at the end
of a meal, no later than 20 minutes after the start of the meal.
During the 26-week treatment period, bolus insulin was titrated
to achieve a glycaemic target of pre-prandial and bedtime plasma glu-
cose (PG) between 4.0 and 6.0 mmol/L. Participants who were consid-
ered proficient in carbohydrate counting continued using this method
for bolus adjustment during the treatment period, while all other par-
ticipants used a predefined bolus-dosing algorithm (Table S3 in
File S1).
Meal carbohydrate content and pre-prandial BG values were used
to determine bolus-insulin doses for participants, based on flexible
dosing principles. Doses were calculated several times daily by each
participant based on the insulin:carbohydrate ratio and insulin correc-
tion factor. Weekly review of the ratio and correction factor was per-
formed by the investigator, based on each participant's self-measured
2886 BUSE ET AL.
blood glucose (SMBG) values. In the event of hypoglycaemia, the dose
could be reduced at the investigator's discretion.
2.4 | Self-measured blood glucose (SMBG)
Participants were supplied with a BG meter (Abbott Precision Neo or
Precision; Abbott Laboratories, Chicago, Illinois) and were instructed
to record the date, time and value of all SMBG measurements relating
to 4-, 7- and 9-point profiles and hypoglycaemic episodes. The
4-point profiles, before each main meal (breakfast, lunch, evening
meal) and at bedtime, were recorded daily for insulin titration pur-
poses. The 7-9-7-point profiles, before and 60 minutes after each
main meal, at bedtime, at 4:00 AM (9-point only) and before breakfast
the following day (9-point only), were recorded on three consecutive
days (7-point profiles for Days 1 and 3, a 9-point profile on Day 2)
before scheduled clinic visits at Weeks 0, 12 and 26.
2.5 | Standardized meal test
Participants were required to attend the standardized meal test with a
fasting SMBG of 4.0 to 8.8 mmoL/L. Before randomization at Week 0
(baseline), a bolus dose of IAsp was administered (0.1 U/kg, calculated
by investigator), followed by a standardized mixed liquid-meal test
(78 g carbohydrate consumed within 12 minutes). Blood samples
were taken immediately before the meal and after 30 minutes, 1, 2,
3 and 4 hours (0 hour defined as start time of meal consumption). The
meal test was repeated at Week 26, using the participant's study med-
ication. Participants randomized to post-meal insulin received a bolus
dose 20 minutes after starting the meal.
2.6 | Assessments
2.6.1 | Primary endpoint
The primary endpoint was change from baseline in HbA1c after
26 weeks of treatment.
2.6.2 | Secondary endpoints
Confirmatory secondary endpoints were change from baseline in
1-hour PPG increment (meal test) and change from baseline in
1,5-anhydroglucitol (1,5-AG), both at Week 26.
Supportive secondary efficacy endpoints were: change from base-
line in fasting plasma glucose (FPG); participants (%) reaching HbA1c
targets (<7.0% [53 mmol/mol]); change from baseline in 30-minute,
1-, 2-, 3- and 4-hour PPG; change from baseline in 30-minute, 2-, 3-
and 4-hour PPG increment (meal test); change from baseline in
7-9-7-point SMBG assessed by the mean of the 7-9-7-point profile,
PPG and PPG increment (at each meal and over all meals); percentage
of participants reaching 1-hour PPG targets (≤7.8 mmol/L); change
from baseline in lipid-lipoprotein profiles; basal, total and individual
mealtime insulin doses (Table S4 in File S1).
Supportive secondary safety endpoints were: treatment-
emergent adverse events (TEAEs), treatment-emergent injection site
reactions; treatment-emergent hypoglycaemic episodes (overall and
after meal [1, 1–2, 2–3 and 3–4 hour timepoints]); physical exami-
nation; vital signs; electrocardiogram; fundoscopy; laboratory
parameters; anti-IAsp antibody development (specific and cross-
reacting with human insulin); and body weight. (See Appendix S1, in
File S1 for TEAEs and treatment-emergent hypoglycaemia
definitions).
2.7 | Statistical methods
All statistical analyses were prespecified. Efficacy endpoints were
summarized using the full analysis set, and results are presented based
on data from all randomized participants for the entire trial period,
which includes data collected after participants prematurely discontin-
ued treatment (in-trial observation period). Safety endpoints were
summarized using the safety analysis set (participants receiving ≥ 1
dose of IAsp or faster aspart). Statistical analysis of primary and sec-
ondary confirmatory endpoints followed a stepwise hierarchical pro-
cedure, which was discontinued after step 4 (Figure S2 and Table S5
in File S1). Non-inferiority, the primary endpoint, was confirmed if the
upper boundary of the two-sided 95% CI was 0.4% or less. Two-sided
P-values are presented unless stated otherwise.
Change from baseline in HbA1c 26 weeks post randomization
was analysed using a statistical model with multiple imputations, in
which, for participants without any available HbA1c measurements at
scheduled visits, HbA1c values were imputed from available informa-
tion from the treatment arm to which the participant had been ran-
domized. Change from baseline in PPG and PPG increment (meal test)
was analysed using an analysis of variance model, and HbA1c and PPG
responder endpoints were analysed using a logistic regression model.
Change from baseline in 7-9-7-point outcomes (mean SMBG, PPG,
PPG increments), 1,5-AG, FPG, lipid-lipoprotein profiles (log-trans-
formed) and body weight were analysed using a model similar to the
statistical model used for the primary endpoint. Number of treatment-
emergent severe or BG-confirmed hypoglycaemic episodes was
analysed using a negative binomial regression model. (Sample-size cal-
culation and further details on statistical methods for primary and sec-
ondary endpoints are provided in Appendix S1, File S1).
3 | RESULTS
3.1 | Trial participants
In total, 1025 participants were randomized to mealtime faster aspart
(n = 342), IAsp (n = 342), or post-meal faster aspart (n = 341), all
exposed to their respective study medications, among whom 1007
participants (98.2%) completed the trial, while 999 participants
(97.5%), similarly distributed across treatment arms, completed the
26-week treatment period without premature discontinuation of ran-
domized treatment (Figure S3 in File S1). The most common reason
for withdrawal from the trial was “withdrawal by subject” (four partici-
pants each in the mealtime faster aspart and IAsp arms, six in the post-
meal faster aspart arm). Seven, nine and ten participants in the
mealtime faster aspart, post-meal faster aspart and mealtime IAsp
arms, respectively, prematurely discontinued randomized treatment.
Baseline demographics and disease characteristics were similar
between the three treatment arms (Table 1).
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3.2 | Efficacy
3.2.1 | Change in HbA1c
During the run-in period, observed mean HbA1c was reduced from 8.1%
(65 mmol/mol) to 7.5% (58 mmol/mol) in participants subsequently ran-
domized to mealtime faster aspart, from 8.0% (63 mmol/mol) to 7.4%
(57 mmol/mol) in those randomized to mealtime IAsp, and from 8.1%
(65 mmol/mol) to 7.4% (57 mmol/mol) in those randomized to post-meal
faster aspart (Figure 1). At the end of the 26-week treatment period,
mean HbA1c was 7.3% (57 mmol/mol), 7.3% (56 mmol/mol) and 7.4%
(57 mmol/mol) in the mealtime faster aspart, mealtime IAsp and post-
meal faster aspart arms, respectively. Non-inferiority of both mealtime
and post-meal faster aspart to mealtime IAsp regarding change from
baseline in HbA1c was confirmed (ETD [95%CI]: mealtime, −0.02%
[−0.11; 0.07], −0.24 mmol/mol [−1.24; 0.76]; post meal, 0.10% [0.004;
0.19]; 1.04 mmol/mol [0.04; 2.04]; one-sided P < 0.001 for non-inferior-
ity). Superiority of mealtime faster aspart vs IAsp regarding change from
baseline in HbA1c could not be confirmed (hierarchical testing discontin-
ued; Table S5 in File S1).
The odds of achieving HbA1c less than 7.0% (53 mmol/mol) were
not statistically significantly different between mealtime faster aspart
and IAsp, or between post-meal faster aspart and mealtime IAsp
(Table S6 in File S1).
3.2.2 | Meal test
Superiority of mealtime faster aspart to IAsp regarding change from
baseline in 1-hour PPG increment was confirmed (ETD [95%CI]:
–0.90 mmol/L [−1.36; −0.45]; P < 0.001) (Figure 2D). Change from
baseline in 30-minute PPG increment was also significantly in favour
of mealtime faster aspart; however, there was no statistical signifi-
cance at other timepoints (Table S6 in File S1). Concerning the post-
meal comparison, change from baseline in 30-minute and 1-hour PPG
increment was significantly in favour of IAsp, with no statistical differ-
ences at other timepoints (Figure 2D, Table S6 in File S1). PPG results,
without adjustment for pre-prandial PG, also favoured mealtime faster
aspart at 30 minutes and 1 hour with ETDs [95%CI] of −0.82 mmol/L
[−1.28; −0.36; P = 0.001] and −1.24 mmol/L [−1.81; −0.67;
P < 0.001], respectively, and no statistical differences were observed
at other timepoints.
3.2.3 | Self-measured blood glucose
Observed mean 9-point SMBG profiles at baseline and after 26 weeks
of treatment were similar between groups (Figure S4 in File S1), and
there were no statistically significant differences in mean SMBG for
mealtime or post-meal comparisons (Table S6 in File S1). Regarding
change from baseline in 1-hour PPG increment (based on SMBG),













Age, y 41.5 (14.4) 41.0 (14.6) 40.8 (14.2) 41.1 (14.4)
Gender, n (% male) 184 (53.8) 186 (54.5) 179 (52.3) 549 (53.6)
Body weight, kg 72.6 (16.6) 71.9 (16.9) 71.8 (17.0) 72.1 (16.8)
BMI, kg/m2 25.1 (4.1) 25.1 (4.4) 25.1 (4.4) 25.1 (4.3)
Duration of diabetes, y 17.6 (12.5) 15.8 (10.6) 16.7 (11.0) 16.7 (11.4)








FPG, mmol/L 6.8 (2.1) 6.9 (2.5) 6.8 (2.5) 6.8 (2.4)
Bolus adjusting method, n (% carbohydrate counting) 142 (41.5) 150 (44.0) 136 (39.8) 428 (41.8)
Abbreviations: Faster aspart, fast-acting insulin aspart; FPG, fasting plasma glucose; SD, standard deviation.
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FIGURE 1 Mean HbA1c over time. During the run-in period, observed mean HbA1c was reduced from 8.1% (65 mmol/mol) to 7.5% (58 mmol/
mol) in participants subsequently randomized to mealtime faster aspart; from 8.0% (63 mmol/mol) to 7.4% (57 mmol/mol) in those randomized to
mealtime insulin aspart; and from 8.1% (65 mmol/mol) to 7.4% (57 mmol/mol) in those randomized to post-meal faster aspart. At the end of the
26-week treatment period, mean HbA1c was 7.3% (57 mmol/mol), 7.3% (56 mmol/mol) and 7.4% (57 mmol/mol) in the mealtime faster aspart,
mealtime insulin aspart and post-meal faster aspart arms, respectively. Error bars:  standard error. All available information, regardless of
treatment discontinuation, was used. Abbreviation: Faster aspart, fast-acting insulin aspart
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ETDs [95%CI] were statistically in favour of mealtime faster aspart at
breakfast (−0.58 mmol/L [−0.99; −0.17]; P = 0.006) and over all meals
(−0.48 mmol/L [−0.74; −0.21]; P < 0.001), and no differences were
reported for the faster aspart post-meal comparison. Change from
baseline in 1-hour PPG, based on SMBG profiles, for any individual
meal (breakfast, lunch, evening meal) or for “all meals” was not statisti-
cally significantly different for mealtime faster aspart vs IAsp
(Table S6 in File S1). However, in the faster aspart post-meal compari-
son, change from baseline in 1-hour PPG for “all meals” was statisti-
cally significant in favour of IAsp (ETD [95%CI] 0.34 mmol/L [0.06;
0.63]). The percentage of participants who achieved 1-hour PPG of
7.8 mmol/L or less was significantly greater with mealtime faster
aspart (27.8%) than with IAsp (21.6%; estimated odds ratio, 1.54 [95%
CI 1.05; 2.26]; P = 0.028). There was no statistically significant differ-
ence in the faster aspart post-meal comparison.
3.2.4 | Other secondary endpoints
After 26 weeks there was a numerical increase in 1,5-AG in the meal-
time faster aspart and IAsp arms, with no significant difference
between the two arms (ETD [95%CI], 0.02 μg/mL [−0.31; 0.34]). In
the post-meal faster aspart arm there was a slight decrease in 1,5-AG,
which was statistically significant vs mealtime IAsp (−0.35 μg/mL
[−0.68; −0.03]; P = 0.035). In all three treatment arms, mean FPG
increased from baseline to Week 12 and decreased thereafter, to
Week 26. Fasting SMBG levels on days when meal tests were per-
formed had to be 4.0–8.8 mmol/L. At Week 12, there was no such






































































































































FIGURE 2 PPG increment after a standardized meal test at Week 26. A, Mealtime faster aspart at Week 26 vs baseline. B, Post-meal faster
aspart at Week 26 vs baseline. C, Mealtime insulin aspart at Week 26 vs baseline. D, Mealtime faster aspart, post-meal faster aspart and mealtime
insulin aspart at Week 26. *P < 0.001 in favour of mealtime faster aspart vs insulin aspart; †P < 0.001 in favour of insulin aspart vs post-meal
faster aspart. Mealtime insulin aspart administered immediately before the liquid meal; post-meal faster aspart administered 20 minutes after the
start of the liquid meal. Error bars:  standard error. All available information, regardless of treatment discontinuation, was used. Abbreviations:
Faster aspart, fast-acting insulin aspart; PPG, postprandial glucose
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requirement. The estimated difference in FPG between mealtime fas-
ter aspart and IAsp at Week 26 was statistically significant (ETD [95%
CI], −0.39 mmol/L [−0.78; −0.0008]; P = 0.05). There was no signifi-
cant difference between post-meal faster aspart and mealtime IAsp
(Table S6 in File S1). No clinically significant differences were seen in
lipid-lipoprotein profiles.
3.3 | Safety
Results concerning hypoglycaemia are presented in Table 2. No statis-
tically significant differences were observed between the faster aspart
(mealtime or post-meal) and IAsp arms regarding the rate of
treatment-emergent severe or BG-confirmed hypoglycaemic episodes,
and the rate of treatment-emergent severe or BG-confirmed hypogly-
caemic episodes during the first, second or third hour after start of a
meal. However, a significant difference in the rate of severe or BG-
confirmed hypoglycaemic episodes occurring 3 to 4 hours after start
of a meal was observed, in favour of mealtime faster aspart vs IAsp
(0.72 [0.54; 0.96]; P = 0.024). No statistically significant difference
between treatment groups was observed concerning mean body
weight at Week 26 (change from baseline: +1.43 kg [mealtime faster
aspart], +1.14 kg [post-meal faster aspart], +1.24 kg [insulin aspart]).
No clinically significant differences between treatment groups
were observed regarding percentage of participants who reported
TEAEs and the overall rate of TEAEs, which was similar between the
three treatment arms (Table S7 in File S1); regarding injection-site and
allergic reactions, which were low in number and evenly distributed
across the three treatment arms (Table S7 in File S1); and regarding
vital signs and the results of physical examination and safety labora-
tory assessments. Additional details are shown in Appendix S1,
File S1.
During the trial, mean and median daily bolus insulin doses
increased by similar amounts in all three treatment groups (Table S7 in
File S1), and the basal/bolus ratio 26 weeks post randomization chan-
ged to a higher proportion of bolus compared with basal insulin across
the three treatment arms (Table S8 in File S1).
4 | DISCUSSION
The results of this study confirm that both mealtime and post-meal
faster aspart, in combination with degludec, were non-inferior to
mealtime IAsp regarding change in HbA1c from baseline to 26 weeks
in individuals with T1D. Furthermore, mealtime faster aspart was
effective in reducing PPG excursions, and superiority to IAsp in
1-hour PPG increment, following a standardized meal test, was con-
firmed. Mean SMBG-derived 1-hour PPG increments also showed a
trend towards improved PPG control, with mealtime faster aspart con-
ferring a significantly lower 1-hour PPG increment than IAsp at break-
fast and also when averaged over all meals. Furthermore, significantly
more participants who received mealtime faster aspart achieved a
1-hour PPG target less than 7.8 mmol/L, based on SMBG, compared
with those who received IAsp. Change in body weight was less than
2 kg in all three treatment arms, which may be expected given that
participants were already on a basal–bolus regimen at baseline.
The improved PPG findings reported in the present study, from
both meal test and SMBG, are consistent with general findings across
the faster aspart clinical trial programme.14,15,17,18 Furthermore, the
results here specifically support the results of the onset 1 study, in
which once- or twice-daily detemir in conjunction with mealtime or
post-meal faster aspart was compared with the same basal regimen
and mealtime IAsp.14 In the onset 1 study, however, there was a sta-
tistically significant difference in HbA1c change after 26 weeks
between mealtime faster aspart and IAsp, unlike in the present study.
Despite the reported improvements in PPG and the similar patient
populations in both studies, it is unclear why a greater difference in
change in HbA1c between mealtime faster aspart and IAsp was not
observed in the present study. There was also a discrepancy between
the two studies in the incidence of meal-related hypoglycaemia at
1 hour after the start of a main meal. In the present study, there was
no significant difference between mealtime faster aspart and IAsp
regarding the rate of severe or BG-confirmed hypoglycaemic episodes
1 hour after a main meal, whereas a statistically significant difference
in favour of IAsp was recorded in the onset 1 study (rate ratio: faster
aspart/IAsp 1.48 [95%CI, 1.11; 1.96]; P = 0.0073).14 Conversely, there
TABLE 2 Treatment-emergent hypoglycaemic events
Faster aspart (mealtime) Faster aspart (post-meal) Insulin aspart (mealtime)
N % E R N % E R N % E R
Treatment-emergent hypoglycaemiaa
Severe 32 9.4 46 0.27 19 5.6 29 0.17 31 9.1 47 0.28
Severe or BG-confirmed 304 88.9 5839 34.09 295 86.5 6707 39.40 302 88.3 6820 40.08
Meal-related severe or BG-confirmed hypoglycaemiaa
Within 1 h after a meal 84 24.6 255 1.49 88 25.8 265 1.56 88 25.7 217 1.28
Between 1 and 2 h after a meal 111 32.5 300 1.75 110 32.3 443 2.60 111 32.5 407 2.39
Between 2 and 3 h after a meal 135 39.5 512 2.99 160 46.9 745 4.38 156 45.6 609 3.58
Between 3 and 4 h after a meal 149 43.6 488 2.85 165 48.4 684 4.02 156 45.6 681 4.00
a Hypoglycaemia was defined as treatment-emergent if the onset of the episode occurred on or after the first day of treatment administration post ran-
domization and no later than 1 d after the last day on treatment. Severe hypoglycaemia was defined according to the American Diabetes Association
classification,16 and BG-confirmed hypoglycaemia was defined as a plasma glucose value <3.1 mmol/L (Novo Nordisk A/S definition), with or without
symptoms consistent with hypoglycaemia.
Abbreviations: %, percentage of participants; BG, blood glucose; E, number of events; faster aspart, fast-acting insulin aspart; N, number of participants;
R, event rate per patient-year of exposure.
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was a significant reduction in meal-related hypoglycaemia in favour of
mealtime faster aspart 3 to 4 hours after a main meal in the present
study. These differences are probably related to the reported left shift
of the concentration–time curve for faster aspart relative to IAsp,
reflective of the faster onset and offset of action of faster aspart.13
While mealtime dosing of insulin is appropriate for many patients
with diabetes, there are situations in which the increased flexibility of
post-meal dosing may be advantageous. During social or other occa-
sions, for example, the timing and/or carbohydrate content of a meal
may be unpredictable. Furthermore, elderly or hospitalized patients, in
whom lack of appetite and nausea are common, may also benefit from
post-meal dosing, as might patients who have forgotten an injection,
or are anxious about severe hypoglycaemia.19,20 Although post-meal
dosing cannot be recommended, the results of the present study sug-
gest that post-meal dosing of faster aspart may be considered in
patients who need it.
This study employed once-daily degludec as the basal insulin.
Degludec is associated with tolerability and overall glycaemic control
similar to other long-acting insulin analogues, with the benefit of a
reduced rate of overall symptomatic hypoglycaemic and severe hypo-
glycaemic events,21–23 which may have contributed to the lower rates
of hypoglycaemia observed here compared with observations during
the onset 1 study.14 In addition, in the present study, an improvement
in glycaemic control, that is, a reduction in HbA1c of approximately
0.6% in each arm, was achieved with weekly titration of degludec
(pre-breakfast target, 4.0–5.0 mmol/L) over the eight-week run-in
period.
Strengths of the onset 8 study include the large patient cohort,
the high percentage of participants who completed the study, the ran-
domized, double-blind design for mealtime groups, and the individual
optimization of basal insulin dose during the run-in period to allow a
clearer comparison of study arms. Furthermore, this is the first study
to evaluate the combination of degludec, a basal insulin proven to
confer fewer hypoglycaemic events, with faster aspart, and the use of
faster aspart post meal. The meal-test protocol was a potential limita-
tion of the study, as the standardized meal composition may not accu-
rately reflect what patients habitually consume. Moreover, all
participants received an insulin dose of 0.1 U/kg for the meal test
without adjustment for individual insulin:carbohydrate ratios. The
meal-test insulin dose was, therefore, only an approximation of the
participant's normal dose. Nevertheless, the reported SMBG 1-hour
PPG increment findings corroborated the meal-test results. Continu-
ous glucose monitoring was not performed; however, monitoring in
prospective studies could help to confirm hypoglycaemic events and
to evaluate the impact of treatment on glucose variability and time in
range.
In conclusion, the findings of this study, together with those
of the onset 1 study, confirm that mealtime and post-meal faster
aspart provide effective HbA1c control in individuals with T1D, as
the findings from both met the criteria for non-inferiority com-
pared with IAsp. Mealtime faster aspart further provides modestly
improved control over early (30-minute and 1-hour) PPG excur-
sions compared with mealtime IAsp. The overall safety profiles for
faster aspart and IAsp are similar and are as expected for the
IAsp formulation. Administration of faster aspart after a meal,
although less favourable compared with mealtime administration,
may be considered for some individuals with T1D under certain
circumstances.
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